JP Morgan Chase’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.4M | Buy |
75,300
+62,800
| +502% | +$29.3M | ﹤0.01% | 1659 |
|
|
2025
Q4 | $5.67M | Sell |
12,500
-15,000
| -55% | -$6.47M | ﹤0.01% | 3192 |
|
|
2025
Q3 | $10.8M | Sell |
27,500
-3,900
| -12% | -$1.63M | ﹤0.01% | 2647 |
|
|
2025
Q2 | $14M | Sell |
31,400
-100
| -0.3% | -$46.1K | ﹤0.01% | 2258 |
|
|
2025
Q1 | $15.3M | Buy |
31,500
+10,500
| +50% | +$4.89M | ﹤0.01% | 2153 |
|
|
2024
Q4 | $8.46M | Hold |
21,000
| – | – | ﹤0.01% | 2851 |
|
|
2024
Q3 | $9.77M | Hold |
21,000
| – | – | ﹤0.01% | 2624 |
|
|
2024
Q2 | $9.84M | Sell |
21,000
-31,100
| -60% | -$13.5M | ﹤0.01% | 2476 |
|
|
2024
Q1 | $21.8M | Sell |
52,100
-30,100
| -37% | -$12.7M | ﹤0.01% | 1821 |
|
|
2023
Q4 | $33.4M | Buy |
82,200
+32,900
| +67% | +$12.2M | ﹤0.01% | 1461 |
|
|
2023
Q3 | $17.1M | Buy |
49,300
+27,100
| +122% | +$9.48M | ﹤0.01% | 1807 |
|
|
2023
Q2 | $7.81M | Sell |
22,200
-1,000
| -4% | -$337K | ﹤0.01% | 2502 |
|
|
2023
Q1 | $7.31M | Buy |
23,200
+8,400
| +57% | +$2.52M | ﹤0.01% | 2536 |
|
|
2022
Q4 | $4.27M | Buy |
14,800
+7,600
| +106% | +$2.32M | ﹤0.01% | 2964 |
|
|
2022
Q3 | $2.08M | Buy |
7,200
+800
| +13% | +$230K | ﹤0.01% | 3426 |
|
|
2022
Q2 | $1.8M | Buy |
6,400
+6,200
| +3,100% | +$1.66M | ﹤0.01% | 3631 |
|
|
2022
Q1 | $52K | Sell |
200
-38,900
| -99% | -$9.23M | ﹤0.01% | 5787 |
|
|
2021
Q4 | $8.59M | Hold |
39,100
| – | – | ﹤0.01% | 2588 |
|
|
2021
Q3 | $7.09M | Hold |
39,100
| – | – | ﹤0.01% | 2726 |
|
|
2021
Q2 | $7.88M | Sell |
39,100
-184,800
| -83% | -$38.7M | ﹤0.01% | 2643 |
|
|
2021
Q1 | $48.1M | Buy |
+223,900
| New | +$49.2M | 0.01% | 1179 |
|
|
2020
Q1 | – | Sell |
-46,300
| Closed | -$10.1M | – | 5762 |
|
|
2019
Q4 | $10.1M | Buy |
46,300
+20,000
| +76% | +$4.05M | ﹤0.01% | 2105 |
|
|
2019
Q3 | $4.46M | Hold |
26,300
| – | – | ﹤0.01% | 2785 |
|
|
2019
Q2 | $4.7M | Sell |
26,300
-35,800
| -58% | -$6.26M | ﹤0.01% | 2700 |
|
|
2019
Q1 | $11.4M | Buy |
62,100
+23,000
| +59% | +$4.25M | ﹤0.01% | 1936 |
|
|
2018
Q4 | $6.48M | Buy |
39,100
+600
| +2% | +$104K | ﹤0.01% | 2365 |
|
|
2018
Q3 | $7.42M | Sell |
38,500
-17,200
| -31% | -$3.06M | ﹤0.01% | 2445 |
|
|
2018
Q2 | $9.47M | Sell |
55,700
-10,700
| -16% | -$1.66M | ﹤0.01% | 2189 |
|
|
2018
Q1 | $10.8M | Buy |
66,400
+46,500
| +234% | +$7.6M | ﹤0.01% | 1970 |
|
|
2017
Q4 | $2.98M | Sell |
19,900
-188,600
| -90% | -$27.9M | ﹤0.01% | 3063 |
|
|
2017
Q3 | $31.2M | Buy |
+208,500
| New | +$31.4M | 0.01% | 1210 |
|
|
2017
Q2 | – | Sell |
-45,400
| Closed | -$4.96M | – | 5246 |
|
|
2017
Q1 | $4.96M | Buy |
+45,400
| New | +$4M | ﹤0.01% | 2430 |
|
|
2015
Q1 | – | Sell |
-120,000
| Closed | -$14.3M | – | 4280 |
|
|
2014
Q4 | $14.3M | Buy |
+120,000
| New | +$13.5M | ﹤0.01% | 1704 |
|
Other funds holding VRTX
VCM
VPM
JP Morgan Chase's VRTX Position: Q1 2026 in Review
JP Morgan Chase increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $463M and bringing the position to 7,033,156 shares worth $3.12B. The position accounts for 0.2% of the portfolio, ranked #109.
JP Morgan Chase first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.76B in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- JP Morgan Chase held 7,033,156 shares of Vertex Pharmaceuticals worth $3.12B as of Q1 2026.
- JP Morgan Chase bought 993,675 Vertex Pharmaceuticals shares in Q1 2026, an estimated $463M.
- Vertex Pharmaceuticals made up 0.2% of JP Morgan Chase's portfolio in Q1 2026, its #109 holding.
- JP Morgan Chase first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Vertex Pharmaceuticals position peaked at $3.76B in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.